TLSA - חוב כולל להון Tiziana Life Sciences, Ltd.

Tiziana Life Sciences (TLSA) relies on principles of environmental responsibility, implementing green chemistry methods for the safe disposal of chemicals. The business is developing therapies at the intersection of oncology and immunology, minimizing patent threats through a variety of drug delivery methods. This chart of the market price shows that the total debt-to-equity ratio is 0.00, while the company implements cloud software and robotic antibody microdosing.

This indicator serves as a key tool for assessing financial stability and default risk. It measures the proportion of borrowed funds relative to net assets, where the value of 0.00 reflects the current degree of dependence on creditors. By analyzing the level of debt load relative to equity, an investor determines the balance between profit leverage and security. The low leverage of Tiziana Life Sciences (TLSA) confirms the efficiency of outsourcing drug synthesis to GMP partners. The absence of production delays minimizes the need for expensive borrowed capital.